Use of Clarithromycin in Mustard-Induced Bronchiolitis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

We looked for the effectiveness of low-dose long-term prescription of clarithromycin in mustard-induced chronic pulmonary lesions, especially bronchiolitis obliterans

• Phase: Phase 3

Details

• Lead Sponsor: Baqiyatallah Medical Sciences University
• Treatments: Clarithromycin

Criteria

Inclusion Criteria:

• His/her own will to participate

• Documented chemical exposure

• Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)

Exclusion Criteria:

• any drug reactions during the trial

• history of sensitivity to macrolides

• diarrhea, gray stool, jaundice, eosinophilia, acute cholestatic hepatitis, pruritis, dark urine, abdominal pain, osteomatosis, depression, taste change, behavioural changes, early fatigue, odynophagia, glossitis , dizziness

• co-adminstration of: terfenadine, theophylline, carbamazepine, ergotamine, dihydroergotamine, warfarin, cisapride, digoxin, triazolam, phenytoin, steroids, any immunosuppressive, any systemic antibiotics

• using drugs that he/she cannot discontinue

• using drugs with potential interaction

• subject will to exit from the trial

• history of lobe resection of lung

• history of exacerbation in the last month prior to the beginning of trial

• continuous need to oxygen

• use of corticosteroids in last week prior to the trial beginning

• Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic

• exacerbating of subjects

• creatinine srum level more than normal

• increasing ALT, AST levels

• total bilirubin more twice than normal

• subjects who did not use their drugs properly